For biopharma IP teams, portfolio managers, R&D leads, and institutional investors who track biologic patent cliffs for a living. 1. […]
Biosimilar Patent Strategy: The Complete IP, Litigation, and Market Entry Playbook Read Post »
Books and Research Papers Citing DrugPatentWatch All Years | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 2025 — 11 Books and Research Papers Citing DrugPatentWatch Gregory, A. (2025).
How Academic Researchers and Policy Experts Use DrugPatentWatch Read Post »
A playbook for IP teams, portfolio managers, and R&D leads — from Paragraph IV mechanics and biosimilar patent dance tactics
The business of generic drug development is often misunderstood as a simple exercise in duplication. For many years, we operated
How commercial manufacturing costs actually get built, what drives them, how CDMOs protect their pricing through IP assets, and what
The patent system did not anticipate generative chemistry. When Congress codified the requirement that inventors be ‘natural persons’ in 35
Who Owns the AI-Discovered Drug? The Patent Ownership Guide Pharma IP Teams Need Now Read Post »
A deep-dive reference for pharma IP teams, portfolio managers, regulatory strategists, and institutional investors tracking generic market entry timelines.
1. What Are Specialty Generics — and Why the Definition Matters Defining the Asset Class With Precision The term ‘specialty
Specialty Generics: The $167B IP Playbook Pharma Analysts Need Now Read Post »
Key Takeaways (Top-Line Summary) Section I: What Precision Medicine Actually Is — and Why Its IP Complexity Is Unmatched Precision
Sign in or create a free account to read this DrugPatentWatch article
